A new annual report released by Sun Life, an international financial services organization and the largest independent stop-loss provider in the U.S., analyzed 60,000 stop-loss claims from a member database of 6 million people. 

The report revealed a number of significant findings, including that cardiovascular disease rose to second place on the list of highest stop-loss claim reimbursements over a four-year period from 2020 to 2023. According to the report, reimbursements for cardiovascular diseases surpassed blood cancers for the first time in 12 years. 

Malignant neoplasm (solid tumors) topped the list of highest reimbursements in 2023 followed by cardiovascular disease, newborn/infant care, orthopedics/musculoskeletal care and leukemia/lymphoma and multiple myeloma. The report found that in 2023, U.S. companies received $415.6 million in reimbursements for malignant neoplasm alone.